ZBH Investor Notice: Levi & Korsinsky Investigates Zimmer Biomet Holdings, Inc. for Securities Law Violations

Core Insights - Zimmer Biomet Holdings, Inc. reported third-quarter 2025 net sales of $2 billion, which fell short of consensus estimates of $2.01 billion [2] - The company revised its full-year organic revenue growth outlook down to a range of 3.5% to 4%, from a previous range of 3.5% to 4.5% [2] - Weakness was noted in international markets and non-core businesses, with specific challenges in the Middle East and Eastern Europe impacting results [2] - Following the earnings announcement, Zimmer Biomet's stock price dropped over 15% on November 5, 2025 [3] Financial Performance - Net sales for Q3 2025 were reported at $2 billion, missing the expected $2.01 billion [2] - The revised outlook for full-year organic revenue growth is now projected at 3.5% to 4% [2] Market Challenges - The company faced challenges in international markets and non-core businesses, leading to a decline in performance [2] - There were specific issues with distributors and order cancellations in the Middle East and Eastern Europe [2] - Analysts expressed concerns regarding lower-than-expected growth in U.S. knee and hip replacement sales, indicating potential operational control issues [2]